UNVEILING THE FISCAL BURDEN OF MIGRAINE IN ARGENTINA

Vega, C.a; Martins, R.b,c, Orlovic, Z.b,d, Paquete, A. T.b, Rey Ares, L.a, Veiga, S.a, Villarreal Ramírez, J.e

a-Pfizer Argentina; b-Global Market Access Solutions, St-Prex, Switzerland, c-University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; d-Faculty of Economics and Business, University of Zagreb, Zagreb, Croatia; e-Pfizer SAS.

Introduction

Migraine is a neurological disorder marked by recurrent headaches that are often unilateral and pulsating in nature. The intensity of the pain can range from moderate to severe and is frequently accompanied by symptoms such as nausea, vomiting, photophobia, and phonophobia. Episodes can last from several hours to multiple days, impairing daily functioning and quality of life^{1,2,3,4}.

Migraine is primarily classified into episodic (EM) and chronic (CM) migraine. Intermittent episodes occurring on less than 14 days per month are defined as EM. CM is defined by the occurrence of headaches on ≥ 15 days per month, with migraine occurring on at last 8 of these days⁴.

According to the Global Burden of Disease Study, migraine is the second cause of disability worldwide. It significantly impacts individuals' quality of life and productivity, contributing to substantial economic burden⁵. Migraine disproportionately affects females across all age groups. In Argentina, prevalence is 14% in females, and 5% in males⁶, increasing with age up to 40 to 44 years and decreasing thereafter⁵.

Argentina has a heterogeneous health system, with nearly 40% of the population relying exclusively on the public healthcare system⁷. Understanding the fiscal burden of migraine can promote sustainability and shape national healthcare policy.


Objectives

We aimed to estimate the fiscal-economic burden of migraine using the Argentinian government perspective.

Methods

A mechanistic model estimating the impact of migraine on productivity, need for government benefit transfers⁸, and public healthcare utilization (Figure 1) was adapted to the Argentinian context.

Figure 1. Migraine model diagram



Acronyms: CM, chronic migraine. EM, episodic migraine. MMDs, monthly migraine days. SS, social security contributions.

Those affected by migraine were compared to demographically identical individuals from the general population (GP).

A cross-sectional model, using the Argentinian demographic distribution and published migraine prevalence rates, estimated the annual burden associated with the entire cohort with prevalent migraine living in Argentina.

A longitudinal model consisting of a Markov lifetable process simulated the fiscal life of an individual from the age of 40, a commonly reported age of peak migraine prevalence⁹, over a 20-year work life expectancy.

Results were reported as incremental fiscal consequences. Direct and indirect taxes resulting from employment earnings, and corporation taxes were considered sources of government revenue, thus shown as positive values. Public sector absenteeism and transfers in the form of healthcare costs and financial support to individuals (unemployment benefits, and disability or early retirement pensions) were represented as negative values. Longitudinal results were discounted annually at 3%. Local inputs were used, and costs were expressed in 2023 US Dollars (1 US\$ = 376 AR\$).

Evidence of migraine's impact on productivity was sourced from peer-reviewed publications identified as result of a targeted literature search conducted on PubMed and Google Scholar. Migraine's impact on labor outcomes increased with disease severity⁹⁻¹².

The extracted relative risks of employment¹⁰, disability¹³, and early retirement¹⁴ were applied to baseline rates of these events in the GP, as informed by national statistics⁷. The annual workdays missed due to EM and CM reported by a European study were used to estimate absenteeism¹⁵. Healthcare costs were estimated using monthly headache days (MHD)¹⁶, healthcare resource use¹⁷, and local unit costs¹⁸. Data on individual financial support was based on official sources¹⁹.

Uncertainty was assessed in sensitivity analysis.

Conflicts of interest

This study was sponsored by Pfizer. RM, ZO, and ATP were paid consultants to Pfizer. CV, LRA, SV, and JVR are employees of Pfizer and report no further conflicts.


References

1- Steiner TJ, et al. The Journal of Headache and Pain. 2014;15. 2- Hjalte F, et al. The Journal of Headache and Pain. 2019;20(1):65. **3-** Stovner LJ, *et al.* The Lancet Neurology. 2018;17(11):954-976 **4-** International Headache Society. Cephalalgia. 2018;38(1):1-211. 5- Safiri S, et al. Pain. 2022;163(2):e293-309. 6- Lisicki M, et al. on behalf of the Headache Group of the

Argentinian Neurological Society. Cephalalgia. 2021; 41(7):821-6.

Results

Migraine Epidemiological Estimates for Argentina



Cross-sectional model

The entire Argentinian population affected by migraine represents incremental fiscal consequences of US\$1,237 millions in 2023 alone, with an average of US\$378 per person and US\$1,220 for those with CM (Figure 2).

Figure 2. Fiscal consequences from the cross-sectional analysis

•				
ı	Migraine population G	eneral population	Incremental	
Public sector absenteeism	-\$648 M	-\$284 M	-\$364 M	29,4%
Direct taxes from employment	\$8.243 M	\$8.413 M	-\$170 M	13,7%
Indirect taxes from employment	\$3.405 M	\$3.476 M	-\$70 M	5,7%
Foregone corporation taxes	-\$256 M	-\$112 M	-\$144 M	11,6%
Unemployment allowances	-\$24 M	-\$23 M	\$0 M	0,0%
Early retirement pension	-\$255 M	-\$246 M	-\$8 M	0,7%
Disability pension	-\$168 M	-\$161 M	-\$7 M	0,6%
Taxes from transfers	\$1.462 M	\$1.457 M	\$5 M	-0,4%
Healthcare costs	-\$478 M	\$0 M	-\$478 M	38,7%
Total	\$11.282 M	\$12.519 M	-\$1.237 M	100,0%
Incremental costs per life year lived with migr	raine	\$	378	
GDP			\$684.521 M	-0,18%
Total public healthcare expenditure			\$19.845 M	-6,2%
	Public sector absenteeism Direct taxes from employment Indirect taxes from employment Foregone corporation taxes Unemployment allowances Early retirement pension Disability pension Taxes from transfers Healthcare costs Total Incremental costs per life year lived with mignature.	Public sector absenteeism -\$648 M Direct taxes from employment \$8.243 M Indirect taxes from employment \$3.405 M Foregone corporation taxes -\$256 M Unemployment allowances -\$24 M Early retirement pension -\$255 M Disability pension -\$168 M Taxes from transfers \$1.462 M Healthcare costs -\$478 M Total \$11.282 M Incremental costs per life year lived with migraine GDP	Direct taxes from employment \$8.243 M \$8.413 M Indirect taxes from employment \$3.405 M \$3.476 M Foregone corporation taxes -\$256 M -\$112 M Unemployment allowances -\$24 M -\$23 M Early retirement pension -\$255 M -\$246 M Disability pension -\$168 M -\$161 M Taxes from transfers \$1.462 M \$1.457 M Healthcare costs -\$478 M \$0 M	Public sector absenteeism -\$648 M -\$284 M -\$364 M Direct taxes from employment \$8.243 M \$8.413 M -\$170 M Indirect taxes from employment \$3.405 M \$3.476 M -\$70 M Direct taxes from employment \$3.405 M \$3.476 M -\$70 M Direct taxes from employment axes -\$256 M -\$112 M -\$144 M Direct taxes from employment axes -\$256 M -\$112 M -\$144 M Direct taxes from taxes -\$256 M -\$12 M -\$144 M Direct taxes from taxes -\$24 M -\$23 M S0 M Direct from the following from the following from the following from the following from taxes from transfers -\$168 M -\$161 M -\$7 M Direct from transfers -\$1.462 M -\$1.457 M S5 M Direct from transfers -\$478 M S0 M -\$478 M DIRECT from the following from the f

Acronyms: GDP, gross domestic product; M, millions (in United Stated Dollars)

Longitudinal model

Over a 20-year period (Figure 3), cumulative fiscal consequences associated with an average patient added to US\$6,505, and to US\$21,670 if CM was present. Approximately 51% and 57% of these costs were related to the public economic consequences of absenteeism in a patient with average migraine severity and CM, respectively.

Figure 3. Fiscal consequences from the longitudinal analysis

		Migraine population Gene	Incremental		
	Public sector absenteeism	-\$4,275	-\$1,873	-\$2,402	36,9%
CONSEQUENCES	Direct taxes from employment	\$46,724	\$47,652	-\$0,928	14,3%
	Indirect taxes from employment	\$19,304	\$19,687	-\$0,383	5,9%
	Foregone corporation taxes	-\$1,339	-\$0,587	-\$0,753	11,6%
	Unemployment allowances	-\$0,084	-\$0,083	-\$0,001	0,0%
8	Early retirement pension	-\$0,562	-\$0,543	-\$0,019	0,3%
C	Disability pension	-\$1,277	-\$1,222	-\$0,055	0,8%
FISCAL	Taxes from transfers	\$0,807	\$0,776	\$0,031	-0,5%
ii.	Healthcare costs	-\$1,996	\$0,000	-\$1,996	30,7%
	Total	\$57.303	\$63.808	-\$6.505	100,0%

Sensitivity Analysis

Figure 4 shows the sensitivity analysis of the longitudinal model results.

Figure 4. Tornado diagram



Acronyms: CM, chronic migraine. EM, episodic migraine. MMDs, monthly migraine days. RR, relative risk. USD, United Stated Dollars.

Discussion

Migraine was predicted to decrease employment and increase absenteeism rates, disability, and early retirement compared to the GP, strongly impacting the public economy. Costs to the entire migraine population were estimated to represent US\$1,237M, US\$378 per average person with migraine, US\$1,220 per person with CM. The societal burden of migraine is anticipated to surpass our estimates as they exclude consequences on the private and informal labor markets, and presenteeism-related productivity losses. This analysis integrates data from different Argentinian economic sectors and includes multiple sources of information that would likely not be captured by a single primary research study.

Conclusions

This analysis shows that migraine is a major public health problem with significant economic impact on Argentinian public expenditure. It highlights the hidden burden of migraine with the aim of improving recognition and management of this often-neglected condition.

7- INDEC Argentina. Censo 2022. Available from: censo.gob.ar/index.php/datos definitivos/ [Accessed: Feb 2024] 8- Connolly MP, et al. Value in Health. 2017;20(2):273-277. 9- Viana M, et al. European Journal of Neurology. 2019;0:1-6 10- Oliveira A, et al. Headache. 2023;63:114-126.

14- Chalmer MA, *et al.* Cephalalgia. 2020. 40(4): 399-406.

15- Vo P, et al. Journal of Headache and Pain. 2018;19(1):82.

11- Blumenfeld AM, et al. Cephalalgia. 2010; 31(3): 301-315. **12-** Payne KA, *et al.* Cephalalgia. 2011; 31(10): 1116-1130. 13- Buse DC, et al. J Neurol Neurosurg Psychiatry. 2010; 81(4): 428-432.

16- Di Tanna GL, et al. BMC Medical Research Methodology. 2019;19(1): 1-11.

17- Souza MNA, et al. Headache. 2022; 62(10): 1302-1311. 18- 3VAL Database. 3Eff, Argentina. [Accessed: Jan 2024]. **19-** ANSES Argentina. Available from: anses.gob.ar [Accessed:

Feb 2024]